Form 4: Myriad Genetics CSO Awarded 23,697 Shares

Myriad Genetics' Chief Scientific Officer, Dale Muzzey, was awarded 23,697 shares of common stock following the achievement of performance metrics for previously granted restricted stock units.

Summary

• Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc. (MYGN), was awarded 23,697 shares of common stock.
• This award stems from performance-based restricted stock units (PSUs) initially granted on March 15, 2023.
• The final award amount was determined on February 2, 2026, by the Compensation and Human Capital Committee, based on the accomplishment of pre-determined performance metrics.
• Each PSU represents a contingent right to receive one share of the company's common stock and is set to vest on March 15, 2026.
• Following this transaction, Dale Muzzey beneficially owns 193,878 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive indicator, as the vesting of performance-based units suggests the company has met internal performance targets, which is generally favorable for investor confidence.

Positives

• The Compensation and Human Capital Committee determined that pre-determined performance metrics were accomplished, leading to the vesting of performance-based restricted stock units.
• The award of 23,697 shares to the Chief Scientific Officer indicates successful achievement of company goals tied to executive compensation.

Future Outlook

The awarded PSUs are scheduled to vest on March 15, 2026, indicating a future event for the full realization of the stock award.

Industry Context

StockSavvy.ai notes that performance-based restricted stock units are a common executive compensation tool in the biotechnology and diagnostics industry, aligning executive incentives with long-term company performance and shareholder value creation. The successful achievement of performance metrics for a Chief Scientific Officer often correlates with progress in R&D pipelines or clinical development, which are critical drivers in this sector.

Comparison to Industry Standards

• This type of performance-based equity award is standard practice across the biotech and healthcare industries, comparable to compensation structures seen at companies like Illumina, Exact Sciences, or Guardant Health, where executive compensation is often tied to specific R&D milestones, revenue targets, or clinical trial progress.
• The vesting of these PSUs suggests Myriad Genetics has met internal performance benchmarks, which is a positive indicator within the competitive diagnostics space.

Corporate Governance

Stakeholder Impact

• Shareholders: The successful achievement of performance metrics leading to executive compensation vesting could be viewed positively, indicating operational success.
• Employees: May signal a positive internal environment where performance goals are being met.

Next Steps

• The awarded performance-based restricted stock units will vest on March 15, 2026.

Key Dates

Recommendation

This Form 4 filing primarily details an executive compensation event (vesting of PSUs due to performance metric achievement). While positive in indicating internal performance, it does not provide new financial results or strategic shifts that would warrant a change in investment recommendation. It's an expected operational update regarding executive incentives.

Keywords

Myriad Genetics, MYGN, Dale Muzzey, Chief Scientific Officer, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, PSUs, Performance Metrics, Executive Compensation, Stock Award